SenesTech: Evolve Field Trials Show 50–79% Decline in Urban Rodent Activity
- SenesTech reports multi-month Evolve deployments substantially reduced urban rodent activity at two monitored sites within five months.
- SenesTech frames results as evidence fertility control reduces rodent populations where bait is consumed; CEO says Evolve works.
- SenesTech acknowledges missing a pre-deployment baseline at one site and frames data as location-specific observations, not broad claims.
Urban Field Trials Show Steep Decline in Rodent Activity After Evolve Deployment
SenesTech reports that multi-month deployments of its Evolve® Rodent Birth Control produce substantial declines in urban rodent activity across two monitored sites, based on a five-month tracking-plate study carried out between August 2025 and January 2026. At Location A, where deployment began in April 2025, the proportion of tracking plates showing rodent presence falls from an average of 74% in August 2025 to 15% in January 2026, a 79% reduction, while track density on plates with activity drops by 88%. At Location B, which has a pre-deployment baseline, plate presence is 98% before placement in August 2025 and 47% after five months of baiting in January 2026, representing just over a 50% reduction accompanied by a 71% decline in track density.
The study uses standardized tracking plates at regular intervals to measure both the proportion of plates with rodent tracks and the relative density of markings, and SenesTech says the results reflect real-world urban conditions. The company notes that Location A lacks pre-deployment baseline data prior to April 2025 but emphasizes that both sites show measurable declines in the prevalence and intensity of rodent activity within five months of Evolve deployment. The findings are set out in a Feb. 18, 2026 PRNewswire release from Surprise, Arizona.
SenesTech frames the results as evidence that fertility control can reduce rodent populations where the bait is consumed and reproduction decreases. Joel Fruendt, SenesTech president and chief executive, says structured field studies and objective data help municipalities and pest management professionals evaluate fertility control within integrated pest management programs, concluding that “Evolve Rodent Birth Control works.” The company highlights the combination of laboratory and field evidence supporting bait uptake and subsequent population declines.
Study Limitations and Operational Notes
SenesTech acknowledges the limitation of missing a pre-deployment baseline at one site and presents the data as location-specific field observations rather than a broad efficacy claim. The company says objective field measurements can guide decisions on additional deployments and scaling to new locations.
Implications for Municipal Pest Programs
SenesTech positions the Evolve data as a tool for municipalities and pest management professionals considering fertility control as part of integrated pest management, arguing the approach can help communities reduce local rodent damage while informing operational choices on deployment timing and coverage.
Related Cashu News

Bristol-Myers Squibb's Reclassification Enhances Growth Potential in Defensive Investment Strategy
Bristol-Myers Squibb Company (Ticker: BMY) undergoes a key reclassification across the Russell indexes, marking a transformative moment for the company. Moving to the Russell 1000 Defensive and Russel…

Vertex Pharmaceuticals' Casgevy Gains FDA Approval for Expanded Sickle Cell Disease Treatment Options
Vertex Pharmaceuticals (Ticker: VRTX) receives a significant boost in its ongoing battle against sickle cell disease with the recent FDA approval of an expanded label for its gene therapy product, Cas…

Gilead Sciences Gains FDA Approval for Trodelvy in First-Line Triple-Negative Breast Cancer Treatment
Gilead Sciences (Ticker: GILD) makes significant strides in oncology therapy with the recent approval of its drug Trodelvy for patients with unresectable or metastatic triple-negative breast cancer. T…

Merck Advances HIV Treatment and Faces Regulatory Scrutiny Amidst Market Success
Merck & Co. (Ticker: MRK) has recently made significant strides in the pharmaceutical landscape, particularly with its advancements in HIV treatment. The company's innovative drug, IDVYNSO, has receiv…